BCL2 and hematologic disorder: ABT-263 (Navitoclax), which targets BCL-2, BCL-XL, and BCL-W, is FDA approved as well for combination therapy in hematological malignancies and is being studied in multiple clinical trials for several solid tumors (ClinicalTrials.gov Identifier: NCT02591095; NCT00878449; NCT00891605).